Vaccination Registration

The State of Ohio COVID-19 Dashboard displays the most recent preliminary data reported to the Ohio Department of Health (ODH) about cases, hospitalizations and deaths in Ohio by selected demographics and county of residence. Click here for the most up to date information.

10/25/23 
The fall ’23-’24 COVID-19 vaccine is now available at the health department for ages 6 months and up by appointment. The COVID-19 vaccine is no longer free to everyone. For most, insurance will cover the cost. Call the health department at 740-992-6626 with questions and to schedule your appointment. Due to circumstances beyond our control at this time, only Pfizer vaccine is available for those with insurance. The Moderna and Novavax COVID-19 vaccines are available for those who are uninsured or underinsured through federal programs.

 

COVID-19 Links

Vaccines for COVID-19
6 Things to Know about COVID-19 Vaccination for Children (Click)
Most Up To Date Guidance On COVID-19 Vaccines (Click)
COVID-19 Vaccination and Myocarditis and Pericarditis (Click)
 
Summary of recent changes (last updated May 1, 2023):
  • Revision of the mRNA COVID-19 vaccination schedule for people who are moderately or severely immunocompromised as follows:
    • At the time of initial vaccination, people ages 6 months and older are recommended to receive 3 bivalent mRNA doses
    • People ages 6 months and older who previously received only monovalent doses are recommended to receive 1 or 2 bivalent mRNA vaccine doses, depending on age and vaccine product
    • People who previously received a bivalent mRNA vaccine dose(s) have the option to receive 1 or more additional bivalent mRNA doses
  • COVID-19 vaccination is recommended for everyone ages 6 months and older in the United States for the prevention of COVID-19. There is currently no FDA-authorized COVID-19 vaccine for children younger than age 6 months.
  • CDC recommends that people ages 6 months and older receive at least 1 bivalent mRNA COVID-19 vaccine.
  • Bivalent mRNA vaccines

    The number of bivalent doses varies by age, vaccine, previous COVID-19 vaccines received, and the presence of moderate or severe immune compromise.

    For people who are not moderately or severely immunocompromised:

    • At the time of initial vaccination, depending on vaccine product, children ages 6 months–4 years are recommended to receive 2 or 3 bivalent mRNA vaccine doses; children age 5 years are recommended to receive 1 or 2 bivalent mRNA vaccine doses
    • People ages 6 years and older who are unvaccinated or previously received only monovalent vaccine doses are recommended to receive 1 bivalent mRNA vaccine dose
    • People ages 65 years and older have the option to receive 1 additional bivalent mRNA vaccine dose

    For people who are moderately or severely immunocompromised:

    • At the time of initial vaccination, people ages 6 months and older are recommended to receive 3 bivalent mRNA doses
    • People ages 6 months and older who previously received only monovalent doses are recommended to receive 1 or 2 bivalent mRNA vaccine doses, depending on age and vaccine product
    • People who previously received a bivalent mRNA vaccine dose(s) have the option to receive 1 or more additional bivalent mRNA doses

    Novavax COVID-19 Vaccine

    People ages 12 years an older who previously received 1 or 2 monovalent Novavax COVID-19 primary series dose(s) are recommended to receive 1 bivalent mRNA vaccine dose. The monovalent Novavax COVID-19 Vaccine remains authorized for use as a 2-dose primary series and as a booster dose in certain limited situations.

    Janssen COVID-19 Vaccine (Not Available)

 

COVID-19 vaccination guidance for people who are not moderately or severely immunocompromised

 

mRNA COVID-19 vaccines

Ages 6 months–4 years

Ages 6 months–4 years
COVID-19 vaccination historyBivalent vaccineNumber of bivalent doses indicated  Interval between doses*
Unvaccinated

Moderna

___or___

Pfizer BioNTech

2   Dose 1 and Dose 2:
4–8 weeks
3  Dose 1 and Dose 2:
3–8 weeks
Dose 2 and dose 3:
At least 8 weeks
1 dose monovalent Moderna Moderna1  4-8 weeks after monovalent dose
2 doses monovalent ModernaModerna1  At least 8 weeks after last monovalent dose
2 doses monovalent Moderna and 1 dose bivalent ModernaNA; previously received 1 bivalent vaccine doseNA  NA
1 dose monovalent Pfizer-BioNTechPfizer BioNTech2  Dose 1: 3–8 weeks after monovalent dose
Dose 1 and Dose 2: At least 8 weeks
2 doses monovalent Pfizer-BioNTechPfizer BioNTech1  At least 8 weeks after last monovalent dose
3 doses monovalent Pfizer-BioNTechPfizer BioNTech1  At least 8 weeks after last monovalent dose
2 doses monovalent Pfizer-BioNTech and 1 dose bivalent Pfizer-BioNTechNA; previously received 1 bivalent vaccine doseNA  NA

Age 5 years

Age 5 years
COVID-19 vaccination historyBivalent vaccineNumber of bivalent doses indicated  Interval between doses*
Unvaccinated

Moderna

___or___

Pfizer BioNTech

2   Dose 1 and Dose 2:
4–8 weeks
1   
1 dose monovalent Moderna

Moderna

___or___

Pfizer BioNTech

1  4–8 weeks after monovalent dose
1  At least 8 weeks after monovalent dose
2 doses monovalent Moderna

Moderna

___or___

Pfizer BioNTech

1  At least 8 weeks after last monovalent dose
1  At least 8 weeks after last monovalent dose
2 doses monovalent Moderna and 1 dose bivalent mRNANA; previously received 1 bivalent vaccine doseNA  NA
1 or more doses monovalent Pfizer-BioNTechPfizer-BioNTech1  At least 8 weeks after last monovalent dose
2 doses monovalent Pfizer-BioNTech and 1 dose bivalent Pfizer-BioNTechNA; previously received 1 bivalent vaccine doseNA  NA
Ever received 1 dose bivalent Pfizer-BioNTech (regardless of monovalent vaccine history)NA; previously received 1 bivalent vaccine doseNA  NA

Ages 6–11 years

Ages 6–11 years
COVID-19 vaccination historyBivalent vaccineNumber of bivalent doses indicated  Interval between doses*
Unvaccinated

Moderna

___or___

Pfizer BioNTech

1  
1  
1 or more doses monovalent mRNA (no doses bivalent mRNA)

Moderna

___or___

Pfizer BioNTech

1  At least 8 weeks after last monovalent dose
1  At least 8 weeks after last monovalent dose
2 or more doses monovalent mRNA and 1 dose bivalent mRNANA; previously received 1 bivalent vaccine doseNA  NA
Ever received 1 dose bivalent mRNA (regardless of monovalent vaccine history)NA; previously received 1 bivalent vaccine doseNA  NA

Ages 12 years and older

Ages 12 years and older
COVID-19 vaccination historyBivalent vaccineNumber of bivalent doses indicated  Interval between doses*
Unvaccinated

Moderna

___or___

Pfizer BioNTech

1  
1  
1 or more doses monovalent mRNA (no doses bivalent mRNA)

Moderna

___or___

Pfizer BioNTech

1  At least 8 weeks after last monovalent dose
1  At least 8 weeks after last monovalent dose
Ever received 1 dose bivalent mRNA (regardless of monovalent vaccine history)NA; previously received 1 bivalent vaccine doseNA  NA
 

Novavax COVID-19 Vaccine

People ages 12 years and older who previously received 1 or more doses of Novavax COVID-19 Vaccine are recommended to receive 1 bivalent mRNA vaccine dose.

12 years and older: Novavax COVID-19 Vaccine
COVID-19 vaccination historyBivalent vaccineNumber of bivalent doses indicated  Interval between doses
1 or more doses of Novavax vaccine

Moderna

___or___

Pfizer BioNTech

1  At least 8 weeks after last monovalent dose
1  At least 8 weeks after last monovalent dose
 

 

COVID-19 vaccination guidance for people who are moderately or severely immunocompromised

Ages 6 months–4 years

Ages 6 months–4 years
COVID-19 vaccination historyBivalent vaccineNumber of bivalent doses indicated*  Interval between doses
Unvaccinated

Moderna

___or___

Pfizer BioNTech

3   Dose 1 and Dose 2:
4 weeks
Dose 2 and Dose 3: At least 4 weeks
3  Dose 1 and Dose 2:
3 weeks
Dose 2 and dose 3:
At least 8 weeks
1 dose monovalent ModernaModerna2  Dose 1: 4 weeks after monovalent dose
Dose 1 and Dose 2:
At least 4 weeks
2 doses monovalent ModernaModerna1  At least 4 weeks after last monovalent dose
3 doses monovalent ModernaModerna1  At least 8 weeks after last monovalent dose
3 doses monovalent Moderna and 1 dose bivalent ModernaSee footnote  
1 dose monovalent Pfizer-BioNTechPfizer-BioNTech2  Dose 1: 3 weeks after monovalent dose
Dose 1 and Dose 2:
At least 8 weeks
2 doses monovalent Pfizer-BioNTechPfizer-BioNTech1  At least 8 weeks after last monovalent dose
3 doses monovalent Pfizer-BioNTechPfizer-BioNTech1  At least 8 weeks after last monovalent dose
2 doses monovalent Pfizer-BioNTech and 1 dose bivalent Pfizer-BioNTechSee footnote  
3 doses of monovalent Pfizer-BioNTech and 1 bivalent Pfizer-BioNTech doseSee footnote  
*People ages 6 months–4 years who are moderately or severely immunocompromised have the option to receive 1 additional dose of a homologous bivalent mRNA vaccine at least 2 months following the last recommended bivalent mRNA COVID-19 vaccine dose. Further additional homologous bivalent dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last COVID-19 vaccine dose.

Ages 5 years

Age 5 years
COVID-19 vaccination historyBivalent vaccineNumber of bivalent doses indicated*  Interval between doses
Unvaccinated

Moderna

___or___

Pfizer BioNTech

3  Dose 1 and Dose 2:
4 weeks
Dose 2 and Dose 3: At least 4 weeks
3  Dose 1 and Dose 2:
3 weeks
Dose 2 and dose 3: At least 4 weeks
1 dose monovalent ModernaModerna2  Dose 1: 4 weeks after monovalent dose
Dose 1 and Dose 2:
At least 4 weeks
2 doses monovalent ModernaModerna1  At least 4 weeks after last monovalent dose
3 doses monovalent Moderna

Moderna

___or___

Pfizer BioNTech

1  At least 8 weeks after last monovalent dose
1  At least 8 weeks after last monovalent dose
3 doses monovalent Moderna and 1 dose bivalent mRNASee footnote  
1 dose monovalent Pfizer-BioNTechPfizer-BioNTech2  Dose 1 and Dose 2:
At least 4 weeks
2 doses monovalent Pfizer-BioNTechPfizer-BioNTech1  At least 4 weeks after last monovalent dose
3 doses monovalent Pfizer-BioNTechPfizer-BioNTech1  At least 8 weeks after last monovalent dose
3 doses monovalent Pfizer-BioNTech and 1 dose bivalent Pfizer-BioNTechSee footnote  

*People age 5 years who are moderately or severely immunocompromised have the option to receive 1 additional dose of a bivalent mRNA vaccine at least 2 months following the last recommended bivalent mRNA COVID-19 vaccine dose. Further additional bivalent dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last COVID-19 vaccine dose. People in this age group who previously received a dose(s) of Pfizer-BioNTech vaccine are authorized to receive only Pfizer-BioNTech vaccine. Recipients who previously received Moderna vaccine are authorized to receive either bivalent mRNA vaccine.

Ages 6-11 years

Ages 6–11 years
COVID-19 vaccination historyBivalent vaccineNumber of bivalent doses indicated*  Interval between doses
Unvaccinated

Moderna

___or___

Pfizer-BioNTech

3  Dose 1 and Dose 2:
4 weeks
Dose 2 and Dose 3:
At least 4 weeks
3  Dose 1 and Dose 2:
3 weeks
Dose 2 and dose 3:
At least 4 weeks
1 dose monovalent ModernaModerna2  Dose 1: 4 weeks after monovalent dose
Dose 1 and Dose 2:
At least 4 weeks
2 doses monovalent ModernaModerna1  At least 4 weeks after last monovalent dose
3 doses monovalent Moderna

Moderna

___or___

Pfizer-BioNTech

1  At least 8 weeks after last monovalent dose
1  At least 8 weeks after last monovalent dose
3 doses monovalent Moderna and 1 dose bivalent mRNASee footnote  
1 dose monovalent Pfizer-BioNTechPfizer-BioNTech2  Dose 1: 3 weeks after monovalent dose
Dose 1 and Dose 2:
At least 4 weeks
2 doses monovalent Pfizer-BioNTechPfizer-BioNTech‡1  At least 4 weeks after last monovalent dose
3 doses monovalent Pfizer-BioNTech

Moderna

___or___

Pfizer-BioNTech

1  At least 8 weeks after last monovalent dose
1  At least 8 weeks after last monovalent dose
3 doses monovalent Pfizer-BioNTech and 1 dose bivalent mRNASee footnote  

*People ages 6–11 years who are moderately or severely immunocompromised have the option to receive 1 additional dose of Moderna COVID-19 Vaccine.  at least 2 months following the last recommended bivalent COVID-19 vaccine dose.

Ages 12 years and older

Ages 12 years and older
COVID-19 vaccination historyBivalent vaccineNumber of bivalent doses indicated*  Interval between doses
Unvaccinated

Moderna

___or___

Pfizer BioNTech

3  Dose 1 and Dose 2:
4 weeks
Dose 2 and Dose 3:
At least 4 weeks
3  Dose 1 and Dose 2:
3 weeks
Dose 2 and dose 3:
At least 4 weeks
1 dose monovalent ModernaModerna2  Dose 1: 4 weeks after monovalent dose
Dose 1 and Dose 2:
At least 4 weeks
2 doses monovalent ModernaModerna1  At least 4 weeks after last monovalent dose
3 doses monovalent Moderna

Moderna

___or___

Pfizer-BioNTech

1  At least 8 weeks after last monovalent dose
1  At least 8 weeks after last monovalent dose
3 doses monovalent Moderna and 1 dose bivalent mRNASee footnote  
1 dose monovalent Pfizer-BioNTechPfizer-BioNTech2  Dose 1: 3 weeks after monovalent dose
Dose 1 and Dose 2: At least 4 weeks
2 doses monovalent PfizerPfizer-BioNTech1  At least 4 weeks after last monovalent dose
3 doses monovalent Pfizer-BioNTech

Moderna

___or___

Pfizer-BioNTech

1  At least 8 weeks after last monovalent dose
1  At least 8 weeks after last monovalent dose
3 doses monovalent Pfizer-BioNTech and 1 dose bivalent mRNASee footnote  

*People ages 12 years and older who are moderately or severely immunocompromised have the option to receive 1 additional dose of Moderna COVID-19 Vaccine.  at least 2 months following the last recommended bivalent COVID-19 vaccine dose.

Novavax COVID-19 Vaccine

People ages 12 years and older who previously received 1 or more doses of Novavax COVID-19 Vaccine are recommended to receive 1 bivalent mRNA vaccine dose.

Novavax COVID-19 Vaccine
COVID-19 vaccination historyBivalent vaccineNumber of bivalent doses indicated*  Interval between doses
1 or 2 doses of Novavax vaccine

Moderna

___or___

Pfizer BioNTech

1  At least 8 weeks after last monovalent dose
1  At least 8 weeks after last monovalent dose
  • Pain, redness & swelling at injection site
  • Tiredness
  • Headache
  • Muscle pain
  • Chills
  • Fever
  • Nausea 

**Talk to your doctor to see if you can take Motrin or Tylenol after injections. It is not recommended to take these meds before injection. (CDC)

**After injection, exercise arm to work out soreness, apply clean, cool washcloth to site and drink plenty of water. (CDC)

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/prepare-for-vaccination.html

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated.html

Meigs County Health Department

  • Location will be given at time of appointment
  • Phone: 740-992-6626

Hopewell Health Pomeroy Dental and Primary Health Care Clinic

  • 41865 Pomeroy Pike Pomeroy, OH 45769
  • Phone: 740-992-0540

Swisher and Lohse

  • 636 E. Main St Pomeroy, OH 45769
  • Phone: 740-992-2955

Fruth Pharmacy

  • 706 W. Main St. Pomeroy, OH 45769
  • 740-992-6491

Fruth Pharmacy (Powell’s Food Fair)

  • 700 E. Main St. Pomeroy, OH 45769
  • 740-992-1536